H. Sung, J. Ferlay, R.L. Siegel, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021)
K.D. Shield, J. Ferlay, A. Jemal, et al., The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J. Clin. 67(1), 51–64 (2017)
J.P. Pignon, A. le Maître, E. Maillard, J. Bourhis, MACH-NC Collaborative Group, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92(1), 4–14 (2009)
J. Bauml, T.Y. Seiwert, D.G. Pfister, et al., Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J. Clin. Oncol. 35(14), 1542–1549 (2017)
Article CAS PubMed PubMed Central Google Scholar
J.D. Schoenfeld, G.J. Hanna, V.Y. Jo, et al., Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 6(10), 1563–1570 (2020)
A. Marabelle, D.T. Le, P.A. Ascierto, et al., Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38(1), 1–10 (2020)
Article CAS PubMed Google Scholar
M.A. Curran, W. Montalvo, H. Yagita, J.P. Allison, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 107(9), 4275–4280 (2010)
Article CAS PubMed PubMed Central ADS Google Scholar
R.L. Ferris, G. Blumenschein Jr, J. Fayette, et al., Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375(19), 1856–1867 (2016)
Article PubMed PubMed Central Google Scholar
L.Q.M. Chow, Head and neck cancer. N. Engl. J. Med. 382(1), 60–72 (2020)
Article CAS PubMed Google Scholar
A. Chakravarthy, S. Henderson, S.M. Thirdborough, et al., Human papillomavirus drives tumor development throughout the head and neck: improved prognosis is associated with an immune response largely restricted to the oropharynx. J. Clin. Oncol. 34(34), 4132–4141 (2016)
Article CAS PubMed PubMed Central Google Scholar
A.C. Chi, T.A. Day, B.W. Neville, Oral cavity and oropharyngeal squamous cell carcinoma–an update. CA Cancer J. Clin. 65(5), 401–421 (2015)
R.L. Ferris, et al., Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J. Immunother. Cancer 9(6), e002568 (2021)
Article PubMed PubMed Central Google Scholar
R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy, J. Yearley, X. Sher, X.Q. Liu, H. Lu, M. Nebozhyn, et al., Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018)
Article PubMed PubMed Central Google Scholar
E.E.W. Cohen, R.B. Bell, C.B. Bifulco, et al., The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J. Immunother. Cancer 7(1), 184 (2019). Published 2019 Jul 15
Article PubMed PubMed Central Google Scholar
M.M. Galvis, G.A. Borges, T.B. Oliveira, et al., Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 150, 102966 (2020)
Y.P. Chen, Y.Q. Wang, J.W. Lv, et al., Identification and validation of novel microenvironment-based immune molecular immunophenotypes of head and neck squamous cell carcinoma: implications for immunotherapy. Ann. Oncol. 30(1), 68–75 (2019)
J.A. Belk, B. Daniel, A.T. Satpathy, Epigenetic regulation of T cell exhaustion. Nat. Immunol. 23(6), 848–860 (2022)
Article CAS PubMed PubMed Central Google Scholar
E. Gangoso, B. Southgate, L. Bradley, et al., Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell 184(9), 2454–2470.e26 (2021)
Article CAS PubMed PubMed Central Google Scholar
G.P. Wagner, K. Kin, V.J. Lynch, Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci. 131(4), 281–285 (2012)
Article CAS PubMed Google Scholar
V. Thorsson, D.L. Gibbs, S.D. Brown, et al., The immune landscape of cancer. Immunity 48(4), 812–830.e14 (2018). [published correction appears in Immunity. 2019 Aug 20;51(2):411-412]
Article CAS PubMed PubMed Central Google Scholar
D.A. Barbie, et al, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462(5), 108–112 (2009)
Article CAS PubMed PubMed Central ADS Google Scholar
S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013)
S. Monti, P. Tamayo, J. Mesirov, et al., Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91–118 (2003)
Y. Șenbabaoğlu, G. Michailidis, J.Z. Li, Critical limitations of consensus clustering in class discovery. Sci. Rep. 4, 6207 (2014). Published 2014 Aug
Article PubMed PubMed Central Google Scholar
L. McInnes, J. Healy, N. Saul, L. Großberger, UMAP: uniform manifold approximation and projection. J. Open Source Softw. 3, 861 (2018)
A.M. Newman, C.L. Liu, M.R. Green, et al., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12(5), 453–457 (2015)
Article CAS PubMed PubMed Central Google Scholar
K. Yoshihara, M. Shahmoradgoli, E. Martinez, et al., Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013)
Article PubMed ADS Google Scholar
M. Lauss, M. Donia, K. Harbst, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat. Commun. 8:1738 (2017)
M.S. Rooney, S.A. Shukla, C.J. Wu, et al., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015)
Article CAS PubMed PubMed Central Google Scholar
D. Aran, Z. Hu, A.J. Butte, xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017)
Article PubMed PubMed Central Google Scholar
D.R. Spigel, A.B. Schrock, D. Fabrizio, et al., Total mutation burden(TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J. Clin. Oncol. 34, 9017–7 (2016)
N. Auslander, Y.I. Wolf, E.V. Koonin, Interplay between DNA damage repair and apoptosis shapes cancer evolution through aneuploidy and microsatellite instability. Nat. Commun. 11(1), 1234 (2020). Published 2020 Mar 6
Article CAS PubMed PubMed Central ADS Google Scholar
Y. Tian, T.J. Morris, A.P. Webster, et al., ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics 33(24), 3982–3984 (2017)
Article CAS PubMed PubMed Central Google Scholar
M.E. Ritchie, B. Phipson, D. Wu, et al., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43(7), e47 (2015)
Article PubMed PubMed Central Google Scholar
Z. Xiong, F. Yang, M. Li, et al., EWAS Open Platform: integrated data, knowledge and toolkit for epigenome-wide association study. Nucleic Acids Res. 50(D1), D1004–D1009 (2022)
Article CAS PubMed Google Scholar
R. Tibshirani, Regression shrinkage and selection via the lasso. J. Roy. Stat. Soc. Ser. B (Methodological) 58, 267–288 (1996)
A.M. Newman, C.L. Liu, M.R. Green, et al., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015)
Article CAS PubMed PubMed Central Google Scholar
A.E. Teschendorff, C.E. Breeze, S.C. Zheng, et al., A comparison of reference-based algorithms for correcting cell-type heterogeneity in epigenome-wide association studies. BMC Bioinform. 18, 105 (2017)
S.C. Zheng, C.E. Breeze, S. Beck, A.E. Teschendorff, Identification of differentially methylated cell types in epigenome-wide association studies. Nat. Methods 15(12), 1059–1066 (2018)
Comments (0)